Shots: Richter signed an asset purchase agreement with Janssen for Evra transdermal contraceptive patch assets outside the US. The total deal value is $263.5M The companies also signed a transitional […]readmore
Tags : Gedeon Richter
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Fresenius Kabi expanded its footprints with the acceptance of MAA and BLA […]readmore
Shots: Mycenax to sell LusiNEX project, including cell banks, CMC technology, intellectual properties, and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments […]readmore
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars […]readmore
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing […]readmore
Shots: Richter has launched Terrosa, a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated […]readmore